Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx).
Gil AwadaLaila Ben SalamaJennifer De CremerJulia Katharina SchwarzeLydia FischbuchLaura SeynaeveStephanie Du FourAnne-Marie VanbinstAlex MichotteHendrik EveraertAnne RogiersPeter TheunsJohnny DuerinckBart NeynsPublished in: Journal for immunotherapy of cancer (2021)
The combination of avelumab plus axitinib has an acceptable toxicity profile but did not meet the prespecified threshold for activity justifying further investigation of this treatment in an unselected population of patients with rGB.